SAM Lawsuit Challenges Cannabis Schedule III Rescheduling: What to Know

Three weeks after the most significant federal cannabis policy change in half a century, the legal counterattack has arrived. Smart Approaches to Marijuana and the National Drug and Alcohol Screening Association filed a lawsuit on May 5 asking a federal court to overturn the Department of Justice's order reclassifying medical cannabis from Schedule I to Schedule III of the Controlled Substances Act.

The challenge was expected. What matters now is whether it has any chance of succeeding and what it means for an industry that has already begun operating under the assumption that Schedule III is the new reality.

What the DOJ Did

On April 23, 2026, Acting Attorney General Todd Blanche signed an order immediately placing two categories of cannabis products into Schedule III: FDA-approved cannabis products like Epidiolex and cannabis products subject to a qualifying state-issued license for medical use.

The order was published in the Federal Register on April 28, making it immediately effective. At the same time, the DEA announced it would open a separate expedited administrative hearing beginning June 29 to consider broader rescheduling that could eventually cover all cannabis, including recreational products.

The practical impact of the April 23 order was immediate. State-licensed medical cannabis operations became eligible for federal DEA registration, potentially gaining access to banking services, tax deductions under Section 280E, and other benefits that had been denied to businesses operating with Schedule I substances. Major multistate operators like Verano Holdings and Green Thumb Industries moved quickly to submit DEA registration applications.

The Legal Challenge

SAM and NDASA's lawsuit targets the procedural and statutory basis of the rescheduling order. Their arguments fall into three main categories.

The Administrative Procedure Act Argument

The challengers argue that the rescheduling order violated the rulemaking requirements of the Administrative Procedure Act, which generally requires federal agencies to provide public notice and an opportunity for comment before implementing significant regulatory changes. The DOJ's order was issued without a traditional notice-and-comment period, which SAM argues renders it procedurally defective.

This is the strongest of the challengers' arguments from a legal perspective. The APA's notice-and-comment requirements exist to ensure that affected parties have an opportunity to weigh in on regulatory changes before they take effect. However, the APA also includes exceptions for situations where an agency finds good cause that notice-and-comment procedures are impracticable, unnecessary, or contrary to the public interest.

The Statutory Authority Argument

SAM also argues that the order exceeds the statutory authority of the Attorney General under the Controlled Substances Act. This argument centers on the interpretation of Section 201 of the CSA, which outlines the process and criteria for scheduling decisions.

The challengers contend that the Attorney General cannot unilaterally reschedule a substance without following the full process outlined in the CSA, which includes obtaining a scientific and medical evaluation from the Department of Health and Human Services. The DOJ's position is that the April 23 order was supported by the existing HHS recommendation and prior analysis.

The Arbitrary and Capricious Argument

Finally, the lawsuit argues that the rescheduling order is arbitrary and capricious and not in accordance with law. This is the broadest and most difficult argument to sustain, as courts generally defer to agency expertise on technical and scientific matters. To prevail on this claim, SAM would need to demonstrate that the DOJ's decision lacked a rational basis, which is a high bar given the extensive scientific analysis that preceded the rescheduling recommendation.

How Courts Are Likely to View This

Federal courts have historically been reluctant to overturn agency scheduling decisions, and the legal precedents in this area generally favor deference to executive branch expertise. However, the procedural arguments, particularly regarding the APA notice-and-comment requirements, present a more uncertain path.

If a court finds that the DOJ was required to conduct a notice-and-comment period before issuing the rescheduling order, it could vacate the order on procedural grounds even while acknowledging the substantive merits of rescheduling. This would not necessarily mean that cannabis would permanently return to Schedule I, but it could create a period of regulatory uncertainty while the DOJ conducts a proper rulemaking process.

The timeline for the lawsuit is also important. Federal litigation moves slowly, and the DEA's broader rescheduling hearing is set to begin on June 29. If the administrative hearing process results in a final rule that goes through full notice-and-comment procedures, it could moot some or all of the legal challenges to the April 23 order.

What It Means for the Industry

For cannabis businesses, the SAM lawsuit creates a layer of uncertainty at a moment when many operators are making significant strategic decisions based on the assumption of Schedule III classification.

Registration and Compliance Decisions

Multistate operators that have submitted or are preparing DEA registration applications must now factor in the possibility, however remote, that the rescheduling order could be vacated. This does not necessarily mean they should stop pursuing registration. The DEA's expedited review process is proceeding, and operators who delay registration could find themselves at a competitive disadvantage if the order survives legal challenge.

Financial Planning and 280E

One of the most significant immediate benefits of Schedule III classification is the potential elimination of Section 280E tax burdens, which have prevented cannabis businesses from deducting ordinary business expenses. Companies that have already begun adjusting their tax planning based on Schedule III status should be aware that a successful legal challenge could reverse those assumptions.

Investor Confidence

The lawsuit adds a note of caution for investors who have been pricing in the benefits of rescheduling. Cannabis stocks, which rallied following the April 23 announcement, could face volatility if the legal challenge gains traction. However, most market analysts view the lawsuit as unlikely to succeed on the merits and expect that even a procedural victory for SAM would result in a temporary setback rather than a permanent reversal.

The Bigger Picture

SAM's lawsuit reflects a broader tension in American cannabis policy. Even as public support for legalization reaches historic highs and federal policy moves toward accommodation, a well-funded opposition continues to fight reclassification at every turn.

The organization has been the most prominent voice against cannabis reform for over a decade, arguing that rescheduling and legalization will lead to increased youth use, impaired driving, and other public health harms. Whether the courts will find these concerns sufficient to override the DOJ's scientific and policy judgment is the question at the heart of the lawsuit.

For now, the industry is proceeding as if Schedule III is the law of the land, which it is. The legal challenge is a risk factor to monitor, not a reason to reverse course. But it serves as a reminder that the path toward federal cannabis reform, even in 2026, remains contested.

The next major milestone is the DEA administrative hearing on June 29, which will determine whether broader rescheduling moves forward through a process that even SAM would have difficulty challenging on procedural grounds.

Looking for a verified shop carrying products like these? Browse Budpedia's dispensary near me directory to find licensed cannabis retailers in your state with up-to-date menus.